Precision Over Prolongation: IPD Meta-Analysis Challenges Routine Hormone Therapy in Recurrent Prostate Cancer

Precision Over Prolongation: IPD Meta-Analysis Challenges Routine Hormone Therapy in Recurrent Prostate Cancer

At the recent oncology conference, Dr. Amar Kishan, Radiation Oncologist at the University of California, Los Angeles (UCLA), presented Abstract 305, a highly anticipated individual patient data (IPD) meta-analysis addressing the optimal patient selection and duration for hormone therapy (HT) combined with post-operative radiotherapy (RT) in recurrent prostate cancer.
Rethinking “Very High-Risk”: Prof. Karim Fizazi on PEACE-2 Results and the Evolution of Prostate Cancer Risk Stratification

Rethinking “Very High-Risk”: Prof. Karim Fizazi on PEACE-2 Results and the Evolution of Prostate Cancer Risk Stratification

During a recent major international oncology congress, Professor Karim Fizazi from the University of Paris-Saclay (Gustave Roussy) presented the first results of the Phase III PEACE-2 trial. This study evaluated whether the addition of cabazitaxel and/or pelvic radiotherapy to the standard of care—androgen deprivation therapy (ADT) combined with prostate radiation—improves outcomes in patients with very high-risk localized prostate cancer.
Combination Therapy Breakthrough Exceeds 5 Years OS! BRCAaway Trial Establishes the Core Role of Abiraterone + Olaparib in BRCA-Mutated mCRPC

Combination Therapy Breakthrough Exceeds 5 Years OS! BRCAaway Trial Establishes the Core Role of Abiraterone + Olaparib in BRCA-Mutated mCRPC

At a recent major oncology academic conference, Professor Maha Hussain from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago presented the latest efficacy and overall survival (OS) data from the BRCAaway trial (Abstract 16). This Phase II clinical trial thoroughly investigated the definitive efficacy and safety profile of abiraterone combined with olaparib versus either agent alone as a first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring DNA repair defects.
Dr. Martin Gleave Deciphers GUNS Study: Triplet Therapy Significantly Increases MRD Rates in Genomically Aggressive Prostate Cancer

Dr. Martin Gleave Deciphers GUNS Study: Triplet Therapy Significantly Increases MRD Rates in Genomically Aggressive Prostate Cancer

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (GU ASCO), Dr. Martin Gleave from the University of British Columbia presented the latest data from the GUNS study (Genomic Umbrella Neoadjuvant Study). The presentation focused on the pathological responses of high-risk prostate cancer (PCa) patients with aggressive genomic alterations treated with neoadjuvant androgen receptor pathway inhibitor (ARPI) triplet versus doublet regimens.
Balancing Efficacy and Well-being: PRO Dynamics and Skeletal Safety in the Phase 3 PSMAddition Trial for mHSPC

Balancing Efficacy and Well-being: PRO Dynamics and Skeletal Safety in the Phase 3 PSMAddition Trial for mHSPC

At a recent international oncology symposium, Michael Morris, MD, from Memorial Sloan Kettering Cancer Center (MSKCC), delivered an in-depth academic report on Abstract #18. The presentation focused on the latest data regarding health-related quality of life (HRQoL), pain, and symptomatic skeletal events (SSE) from the Phase 3 PSMAddition study. This trial evaluates the efficacy and safety of 177Lu-PSMA-617 in combination with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) for patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). Below is a summary of the core findings.
EBRT vs. Brachytherapy Boost in Localized Prostate Cancer: In-Depth Analysis of 15-Year OS and PCSM Data from the ASCENDE-RT Trial

EBRT vs. Brachytherapy Boost in Localized Prostate Cancer: In-Depth Analysis of 15-Year OS and PCSM Data from the ASCENDE-RT Trial

At a recent international oncology conference, Professor Scott Tyldesley from Vancouver, Canada, delivered an oral presentation on behalf of Professor Jim Morris, sharing the 15-year long-term survival analysis of the ASCENDE-RT trial (Abstract No. 306). This study compared the long-term overall survival (OS) and prostate cancer-specific mortality (PCSM) of an external beam radiotherapy (EBRT) boost versus a low-dose-rate (LDR) brachytherapy boost in patients with localized prostate cancer. Oncology Frontier (Mediamedic) has summarized the core academic highlights to share with our readers.
Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Recently, the upper urinary tract reconstruction team led by Xuesong Li, Director of the Department of Urology at Peking University First Hospital, successfully performed a domestic surgical robot–assisted laparoscopic fully intracorporeal autologous kidney transplantation for a patient with complex upper urinary tract obstruction.
Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology

Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology

At the beginning of 2026, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was grandly held in Beijing. The meeting focused on frontier advances and standardized practices in urologic oncology and brought together numerous domestic experts and scholars in the field.
Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on cutting-edge topics in the diagnosis and treatment of urologic malignancies, aiming to establish a high-level academic exchange platform and to promote innovation in clinical thinking and standardized practice among young physicians.
Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

Published in The BMJ: Professor Xu Zhang’s Team Conducts the World’s First RCT Demonstrating That the Reliability of Telesurgery Is Non-Inferior to Local Robotic Surgery

On January 28, a landmark study was published in the world-leading medical journal The BMJ. For the first time, a multicenter randomized controlled trial (RCT) has demonstrated that the reliability of urological telesurgery is non-inferior to conventional local robotic surgery.